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Background. The mechanism behind the association between human leukocyte antigen (HLA) molecules and the rate of HIV-1
disease progression is still poorly understood. Recent data suggest that ‘‘protective’’ HLA molecules, i.e. those associated with
a low HIV-1 viral load and relatively slow disease progression, tend to present epitopes from the Gag capsid protein. Although
this suggests that preferential targeting of Gag delays disease progression, the apparent preference for Gag could also be
a side-effect of the relatively high immunogenicity of the protein. Methods and Findings. To separate cause and effect, we
predicted HIV-1 epitopes from the whole genome of HIV-1, and found that protective HLA alleles have a true preference for the
p24 Gag protein, while non-protective HLA alleles preferentially target HIV-1 Nef. In line with this, we found a significant
negative correlation between the predicted affinity of the best-binding p24 epitopes and the relative hazard of HIV-1 disease
progression for a large number of HLA molecules. When the epitopes targeted by protective HLA alleles were mapped to the
known p24 structure, we found that mutations in these epitopes are likely to disturb the p24 dimer structure, which is
expected to severely reduce the fitness of the virus. Conclusions. Our results suggest that the intrinsic preference of different
HLA molecules to present p24 peptides explains why some HLA molecules are more protective than others.
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INTRODUCTION
There is increasing evidence that human leukocyte antigen (HLA)
molecules influence the rate of disease progression after HIV-1
infection (reviewed in [1]). Cytotoxic T lymphocyte (CTL)
responses against HIV-1 assert a strong evolutionary pressure on
the virus, causing selection of HIV-1 variants that successfully
escape recognition by CTL [2–4]. Due to the large polymorphism
of HLA molecules, different individuals are able to respond to
specific immunodominant HIV-1 epitopes depending on their
HLA background. Since disease progression is influenced by an
individual’s HLA background, some CTL responses apparently
control the virus better than others.
HLA-B57 molecules have been found to have the strongest
association with immune control of HIV-1 (see e.g. [5,6]). Among
elite suppressors of HIV, i.e. HIV-infected individuals with normal
CD4
+ T cell counts and viral loads below the detection level
without therapy, HLA-B57 molecules are significantly overrepre-
sented [7]. HLA-B57 restricted CTL responses tend to be more
responsive and immunodominant than other CTL responses [8–
10]. HLA-B58 and HLA-B63 have binding motifs that are very
similar to HLA-B57 and are also associated with good immune
control of HIV-1 [1,11]. The protective effect of HLA-B27,
another HLA type associated with long term non-progression [1],
has been proposed to be due to the very conserved Gag epitope it
presents [12]. HLA-B35 and HLA-B53, on the other hand, tend to
be associated with relatively rapid progression to AIDS [1],
although different associations have been found for different HLA-
subtypes: while HLA-B3503 is associated with rapid progression to
AIDS, the rate of disease progression of individuals with HLA-
B3501 (which has only a slightly different peptide-binding motif)
does not differ from the population average [13].
The frequency of HLA molecules in the human population has
been proposed to play a role in the association between HLA
molecules and the rate of disease progression. Firstly, individuals
with rare HLA molecules are more likely to be heterozygous at the
HLA loci, and are thereby expected to induce an immune
response against a larger diversity of peptides than homozygous
individuals. Indeed, HLA-heterozygosity is associated with rela-
tively slow disease progression in HIV-1 infection [13,14].
Secondly, since HIV-1 evolution occurs in the context of the
HLA background of the human population, HIV-1 may be better
adapted to common than to rare HLA molecules [15–17].
However, a large study establishing the relative hazard of HIV-1
disease progression for different HLA molecules found no
correlation between the relative hazard and the population
frequency of HLA molecules [13].
Alternatively, qualitative differences between HLA molecules in
terms of the specific HIV peptides that they present may explain
the association between HLA molecules and the rate of HIV
disease progression. It has recently become clear that individuals
with slow HIV-1 disease progression tend to make broad and
strong CTL responses against HIV-1 Gag, while individuals with
rapid disease progression and high HIV-1 viral loads make strong
CTL responses to Env and accessory/regulatory proteins [7,18–
25]. It is tempting to conclude from these data that certain HLA
alleles provide better protection against HIV-1 disease progression
because of their tendency to induce CTL responses to HIV-1 Gag.
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and slow disease progression could, however, also be due to the
relatively high immunogenicity of HIV-Gag [26], which would
give a bias towards the detection of Gag-specific responses in
individuals with low viral loads. In the latter case, the observed
association between HLA molecules with a low relative hazard
and CTL responses against Gag would not be the cause but the
consequence of low viral loads.
To separate cause and effect, we studied the binding preferences
of different HLA alleles for the different HIV proteins using HLA-
peptide prediction tools. The use of prediction tools, instead of
clinical data, is crucial in this analysis, because prediction tools will
reveal unbiased preferences of HLA alleles for different HIV-1
proteins, whereas HLA-restricted HIV-1 epitopes reported in the
HIV-1 database may be biased, because some HIV-1 proteins are
studied more extensively than others. We found that HLA
molecules associated with slow HIV disease progression have an
intrinsic preference to present epitopes from the p24 Gag capsid
protein of HIV-1. Analysis of the structure of the p24 protein
pointed out that CTL escape mutations restricted by protective
HLA molecules are likely to disturb the ability of p24 to form
a dimer and thereby to result in a drastic viral fitness loss. Taken
together, our analyses suggest that differences between HLA
molecules in the tendency to present peptides from p24 underlie
the association between HLA molecules and the rate of HIV-1
disease progression.
METHODS
Data
Theconsensus andancestralsequences for differentHIV proteins,as
well as 59 individual world-wide HIV-1 clade B p24 sequences with
known year of sampling were downloaded from the Los Alamos
HIV database at www.hiv.lanl.gov/ (consensus August 2004).
HLA-peptide binding predictions
We used two different algorithms to predict the binding affinities
of HIV-1 peptides (of length 9 and 10) to HLA molecules: the
stabilized matrix method (SMM), available at www.immuneepitope.
org [27], and an artificial neural network (ANN), NetMHC3.0
available at www.cbs.dtu.dk/services/NetMHC-3.0/ [28,29]. For
HLA-B3503 we used the only method that is currently available, i.e.
the generalmatrix method at www.cbs.dtu.dk/services/NetMHC-3.
0/. Since prediction scores from these algorithms for different HLA
molecules cannot be compared directly, we either used the ranks of
these peptides among all HIV-1 peptides, or applied an HLA-
binding affinity normalization as previously proposed [30]. Briefly,
the HLA-binding affinities of HIV-1 peptides were divided by an
HLA-specific threshold, which was based on the top 1% binding
affinities of a large set of non-HIV peptides.
Sequence logos
Sequence logos [31] were made to visualize i) to what extent
a position in a sequence is conserved (given by the height of a bar,
i.e. the information content) and ii) which amino acids are most
frequently found at a particular position (the height of each amino
acid in the logo is proportional to the frequency of occurrence at
that position). Sequence logos were generated using the Shannon
information content [32]. The maximum information content is
log 2 20=4.3, which is obtained if the same amino acid is always
observed at a particular position. The minimum Shannon
information is zero, which is obtained if all amino acids occur at
the same frequency at a position.
RESULTS
Protective HLA alleles preferentially target the p24
protein
To investigate whether the recently reported association between
HLA molecules conferring slow HIV-1 disease progression and
CTL responses against Gag [7,18–24] is due to intrinsic properties
of HLA molecules or is a side-effect of the high immunogenicity of
Gag, we analyzed HLA-peptide binding predictions for a large
number of different HLA molecules. We studied the HLA-binding
affinities of HIV-1 peptides for HLA-B5701, B5801, and B2705,
three HLA alleles with a clearly low relative hazard (RH) of HIV
disease progression [1] (Figure 1, Low RH, open and shaded
symbols), and for HLA-B3503 and B5301, which are both
associated with relatively rapid HIV-1 disease progression [1]
(Figure 1, High RH, solid symbols). Predictions were made for all
peptides of length nine and ten from the consensus sequence of
HIV-1 clade B, using the stabilized matrix method [27], and an
artificial neural network [28,29] (see Methods). The HIV-1
epitopes were subsequently ranked by their predicted HLA-
binding affinity within all HIV proteins. We plotted the ranks of
the three best-binding peptides from each HIV-1 protein among
all other HIV epitopes, because Kiepiela et al. [23] reported that
the presence of CTL responses against at least two Gag-epitopes is
associated with a low HIV-1 viral load.
Figure 1 shows that the three HLA alleles with a low RH have
a significantly stronger preference for peptides from p24 than the
two HLA alleles with a high RH (Mann-Whitney, p=0.01), while
the latter have a stronger preference for peptides from Nef (Mann-
Whitney, p=0.02). These differences remain significant when
correcting for multiple tests of significance using the improved
Bonferroni procedure [33]. It is also evident from Figure 1 that,
despite the relatively small size of the p24 protein (7.5% of the
HIV-1 proteome), many of the best-binding peptides for HLA
alleles with a low RH come from p24. For HLA molecules with
a low RH, the average rank of epitopes from p24 is comparable to
the epitopes from the much larger proteins Env and Pol. The other
relatively small HIV-1 proteins (p17, Vpr, Vpu, Tat, Vif and Rev)
contain hardly any of the high ranking epitopes. Of note, both
HLA-B5701 and B5801 appeared to have three very good-binding
p24 epitopes, all ranking within the first ten among all HIV
peptides. In contrast, HLA-B2705 was found to have only a single
good-binding p24 epitope (see Figure 1, shaded symbols).
For a large number of HLA molecules, we plotted the predicted
affinity score of the three best-binding p24 epitopes as a function of
the relative hazard of the corresponding HLA type as defined by
Gao et al. [13] (see Figure 2). It was previously established that
these relative hazards do not significantly correlate with the
frequencies of the HLA molecules in the human population
(Kendall’s t=20.08, p=0.52, [13]). In contrast, we found a clear
correlation between the affinity score of the best-binding p24
epitopes from 59 different individual HIV-1 clade B sequences and
the RH of HIV-1 disease progression for 27 different HLA types
(Figure 2A). Since the data from different HIV-1 clade B
sequences are not independent, we used the consensus HIV-1
clade B sequence to test the significance of this correlation. This
revealed a significant correlation between the binding affinity of
epitopes from HIV-1 clade B p24 and the risk of HIV-1 disease
progression (Kendall’s t=20.17, p=0.029, see Figure 2B). The
best-binding HIV-1 clade B p24 peptides restricted by the
protective HLA types B58 and B57 turned out to have significantly
higher predicted affinity scores (purple and blue circles in
Figure 2B) than those restricted by all other HLA alleles (Mann-
Whitney, p=0.0009). For none of the other HIV-1 clade B
HLA-Related HIV-1 Progression
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best-binding peptides and the relative hazard of disease pro-
gression of the different HLA types was found (not shown).
Obviously, the HLA binding affinity does not have to correlate
directly with immunogenicity or antiviral CTL response. Howev-
er, as pointed out recently [34], HLA-binding is the most
restrictive step in determining immunodominance. Taken togeth-
er, these results suggest that the experimentally observed
association between protective HLA alleles and responses against
Gag is caused by an intrinsic preference of these HLA alleles for
peptides from p24, and is not merely a side-effect of the high
immunogenicity of Gag. The antigen processing efficacy (here
measured as a combination of proteasome cleavage predictions
[35] and predicted TAP binding affinity [36]) does not influence
this intrinsic preference (results not shown).
If HIV-1 were adapting to the most common HLA alleles in the
human population, one could argue that the current HIV-1
consensus sequence in the Caucasian population should contain
more CTL escape mutations for common HLA types, such as
HLA-B35, than for rare HLA types, such as HLA-B57, B58 and
B27. We therefore repeated our analysis using the predicted
ancestral sequence for HIV-1 subtype B and the HXB2 strain
dating from 1983 (see Methods and [37]), which should contain no
or only few CTL escape mutations. Both the HXB2 and the
ancestralsequencedifferedbyonly2aminoacidsfromtheconsensus
HIV-1 clade B sequence; as a consequence there was hardly any
difference between the predicted p24 epitopes from the consensus
and the ancestral HIV-1 clade B sequences, and HXB2 for the
various HLA types (results not shown). Additionally, the binding
affinities of p24 epitopes from the consensus sequence of HIV-1
clade C, the major HIV-1 subtype in large parts of Africa, correlated
significantlywith the relativehazardofthese HLA alleles inthe Afro-
American population [13] (Figure 2C). These observations demon-
stratethat ourresults arenot due to frequency-dependent adaptation
ofHIV-1tothemostcommonHLAallelesinthehumanpopulation,
and therebyconfirmthat HLAtypeswitha low RH have an intrinsic
preference for peptides from p24.
Preferential binding of p24 is due to sequence
patterns
The differential targeting of p24 and Nef by protective and non-
protective HLA alleles could be due to differences in the amino
acid distributions or in the sequence patterns between the two
proteins. When the amino acid residues occurring in p24 and Nef
were completely shuffled (without changing the amino acid
frequencies of the two proteins), both proteins were no longer
preferentially targeted by any of the HLA alleles (results not
shown). This suggests that p24 and Nef carry distinct sequence
patterns that are preferred by HLA alleles with a low or high RH,
respectively. To study the sequence patterns preferred by
protective and non-protective HLA alleles, we devised sequence
logos for both groups of HLA alleles, based on a large set of
experimentally verified good-binding peptides (data available at
www.immuneepitope.org). Since HLA-B57 and B58, and HLA-
B35 and B53 are known to have similar binding motifs [38] we
generated combined binding logos for the HLA alleles with low
and high RH (see Figure 3). The sequence logos point out that the
two groups of alleles have non-overlapping preferences, and target
very different HIV-1 peptides. Taken together, the HLA-peptide
binding data suggest that different sequence patterns occurring in
HIV-1 p24 and Nef are causing the preferential binding of p24
and Nef peptides by HLA alleles associated with slow and rapid
disease progression, respectively.
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Figure 1. Predicted ranks of epitopes from different HIV-1 proteins. HLA-binding epitopes were predicted for HLA alleles with a low RH (HLA-
B5701, HLA-B5801 and HLA-B2705) and HLA alleles with a high RH (HLA-B3503 and B5301), and their rank among all other HIV-1 epitopes was
plotted. Low ranks correspond to good binding peptides. The analyses were limited to the three best-binding epitopes from each HIV-1 protein. HLA
alleles with a low RH were found to have a significantly higher preference for peptides from p24 than HLA alleles with a high RH (p=0.01, Mann-
Whitney test), while HLA alleles with a high RH had a significantly higher preference for Nef (p=0.02). A significant difference between low and high
RH HLA molecules was also observed for peptides from Vpu (p=0.01), p17 (p=0.02), Vif (p=0.02), and Rev (p=0.01), but the median ranks of the
best-binding peptides from these proteins are so high that these differences are probably not physiologically important. Epitopes for HLA-B2705 are
depicted as shaded circles. All predictions were based on a neural-network based predictor (NetMHC); the use of matrix methods gave similar results
(results not shown). The number of amino acids in each of the HIV proteins is: p24 231, Nef 206, Env 856, Pol 947, Vpr 96, Vpu 82, Tat 101, p17 132, Vif
192, and Rev 116 amino acids.
doi:10.1371/journal.pone.0000920.g001
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Based on the suggestion that CTL responses directed against p24
slow down disease progression, we investigated which other HLA
molecules and CTL epitopes are likely to be associated with slow
disease progression, by predicting the p24 epitopes (based on
consensus HIV-1 clade B) for 19 different (4-digit) HLA-A and 16
HLA-B alleles. The p24 peptides that are predicted to be among
the 10 best-binding HIV peptides for each HLA molecule, which
are all expected to be very good HLA binders, are summarized in
Table 1. None of the HLA alleles with a high RH had a p24
epitope with a rank lower than 20. One forth of all epitopes in
Table 1 are presented by HLA alleles with a binding motif very
similar to HLA-B58 (belonging to the B58 supertype [38]).
Interestingly, none of the good-binding p24 peptides came from
HLA-B5802, while 4 good-binding p24 peptides came from HLA-
B5801, which is fully in line with the recent observation that HLA-
B5801 is associated with slow disease progression, while B-5802 is
not [23]. We predict HLA-A6901 to be a protective HLA allele,
having three very good, possibly immunodominant, p24 epitopes
(see Table 1). This relatively rare HLA allele is not widely reported
to be associated with slow HIV disease progression, even though
HLA-A6901 has a RH as low as 0.47 [13], which is even lower
than the RH of HLA-B57. Some of the other alleles in Table 1,
including A0301, A2402, A2403, B0801 and B4501, have been
reported to have a low RH among African-Americans [13]. In
principle, all 18 HLA alleles and all CTL epitopes listed in Table 1
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Figure 2. Relationship between relative hazard and predicted HLA-binding affinity for p24 epitopes. The relationship between the relative hazard
of HIV-1 disease progression and the predicted affinity of p24 peptides plotted for different HLA alleles. The graphs show the normalized predicted
affinity of the three best-binding p24 epitopes for each HLA allele. Data were based on (A) the Caucasian RH of 27 different HLA alleles [13] and 59
individual HIV-1 clade B sequences downloaded from the Los Alamos database, (B) the Caucasian RH of 27 different HLA alleles [13] and the
consensus HIV-1 clade B sequence, and (C) the African RH of 24 different HLA alleles for which non-trivial RH have been determined [13] and the
consensus HIV-1 clade C sequence. The RH values represent the relative hazard of the 2-digit HLA serotype (except for HLA-B3503 and B3501 for
which separate RH are known [13]), while the predicted affinities were based on prediction tools for the 4-digit HLA allele that dominates the 2-digit
HLA serotype (except for HLA-A0205 and HLA-B5802, which dominate the HLA serotypes HLA-A02 and HLA-B58 in Africans, but for which no high
quality prediction tools are available; when they were omitted from the analysis in panel (C), the correlation remained significant (p=0.014)). Because
binding motifs of HLA molecules are not always independent, we repeated the analysis by randomly selecting only one peptide, when a peptide
binds more than one allele. In all cases the analysis for HIV-1 clade B and clade C remained significant (p,0.02). All HLA-peptide binding predictions
were based on matrix methods; very similar results were obtained when using NetMHC, or when we confined our analyses to the best-binding p24
peptide for each HLA type.
doi:10.1371/journal.pone.0000920.g002
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percent of these CTL epitopes remain to be experimentally
confirmed.
Why is preferential targeting of p24 protective?
Why would preferential targeting of the p24 protein provide better
protection against HIV disease progression than immune
responses to other HIV-1 proteins? A likely contributor is the
fact that the p24 capsid protein is one of the most functionally and
structurally constrained proteins of HIV-1 [3,26,39]. It has been
shown that point mutations in the capsid surface markedly reduce
viral fitness [3,40,41]. In contrast to such constraints on p24, the
Nef protein is known to be polymorphic [26]. During acute
infection, immune responses to Nef are typically replaced by
responses to more conserved regions of HIV-1 [42]. The level of
protection conferred by different HLA molecules may correlate
with the loss of viral fitness resulting from CTL escape; a large
viral fitness cost may either lead to less frequent CTL escape or to
viral attenuation upon CTL escape.
The epitopes targeted by protective HLA alleles indeed lie in
relatively constrained regions of the p24 protein. The epitope
TSTLQEQIGW (TW10, p24 positions 108 to 117) was found to
trigger an immunodominant CTL response in individuals
expressing HLA-B57 or B58 [9]. Mutations in this epitope allow
for CTL escape, but are associated with a large viral fitness cost.
For example, the ThrRAsn mutation at p24–110 causes a 10-fold
reduction in the replication rate of the virus [3]. Similarly,
AlaRGlu escape in another HLA-B57 immunodominant epitope,
KAFSPEVIPMF (KF11, p24 positions 30 to 40), severely reduces
the viral replicative capacity [43]. In the crystal structure of p24
[44], the N-terminal domain can be seen to form a homo-dimer
[45], which is known to be important in Gag assembly [46–48].
The two monomers have contact at three extended regions (see
Figure 4A), two of which have been shown to contain CTL
epitopes that induce protective responses in HLA-B57 or B58-
positive individuals (i.e. TW10 and ISPRTLNAW, IW9, p24
positions 15-23 [5]). The third region at the dimer interface
(QDLNMMLNIVGG, p24 positions 50-61) contains an epitope
restricted by HLA-B14 (DLNMMLNIV, DV9) [49], which is also
associated with a low relative hazard of HIV disease progression
(RH=0.7 [13]). Recently, Martinez-Picado et al. [50] proposed
that the reduced fitness of the T110N mutant is due to the loss of
the hydrogen bond between the side chain of the hydroxyl group
of T110 and the backbone amide of E113, which would destabilize
helix 6 of the N-terminal domain of p24. Analysis of the dimeric
structure of p24 shows that T110 also has a very central position at
the protein-protein interface, being one of three residues that are
in contact with their corresponding residue in the other monomer
(see Figure 4B). If the threonine residue is replaced by an
asparagine, the symmetric hydrophobic contact is replaced by
a polar contact, which is expected to disturb the dimeric interface,
and thereby to destabilize the HIV capsid. In combination with
the intramolecular destabilizing effect on helix 6, this destabiliza-
tion of the HIV capsid may explain why CTL escape mutations at
these sites are associated with a large viral fitness cost.
DISCUSSION
Our results demonstrate that the association between HLA
molecules conferring slow HIV-1 disease progression and CTL
responses to HIV-1 Gag is due to an intrinsic preference of these
HLA alleles for peptides from the p24 protein, and not merely
a side-effect of the high immunogenicity of the Gag protein.
Several recent studies have also established a link between low
HIV viral loads and CTL responses against Gag or p24 [7,18–24].
Bailey et al. [7] reported that CTL responses in elite suppressors of
HIV infection focus on HLA-B57 restricted Gag epitopes.
Moreover, a significant negative correlation between the magni-
tude of the CD8 T cell response and HIV-1 viral load was only
found for responses against p24 and not for responses against other
HIV-1 proteins [20,22,23]. When we performed a partial correla-
tion on data published by Frahm et al. [26], who determined CTL
responses to a large panel of HIV-1 peptides spanning all HIV-1
proteins in 150 infected individuals, we found that the number of
CTL responses directed against p24 correlated positively with the
CD4
+ T cell count (p=0.04) and negatively with viral load
(p=0.01), while the number of CTL responses against Nef
correlated positively with viral load (p=0.03) and not with the
CD4
+ T cell count (p=0.96) (unpublished results). Interestingly,
the main HIV-1 specific CTL responses in chimpanzees, which
have a low viral load and do not develop AIDS, have been found
0
1
2 |
1
  G P C K A D W
R
Q
H
T
N
S
V
Y
E I M L
F
2
  C R E
H Y
G T
I M
F
Q
V
S
L
A P
3
  C H M Q W R T D P K N E
G
F
A
Y
L
I
S
V
4
  H W M Q K Y G F C A L D N T V
R
I E
S P
5
  H W K C Y M V R N F E D Q
I T
S
A
G P
L
6
  C H W Y M K P
E
T
V
R
I
N D
A
S
G
F
Q L
7
  C G M K R W H D E I P
Y
F
T
N
A
S L
Q V
8
  W Q H C M D
F G
K Y
N
R E V
S
L
T I
P
A
9
  K Q E T
G
S H W A
V M Y
I
L
F
0
1
2 |
1
  C E M Q A
F
W
S
H
G
L
T V R I K Y
2
  N P I
F
G
Q V M L A S T
3
  E P C Q K R M
W
H T V N
G
S
L
Y
I
D
F A
4
  Y T W
N
H A
L
S
I
R
D
F
K G E
Q P V
5
  R M L W
Q
N
H
D
C F
E
Y
S
P
G
K
A
T
I V
6
  E M W K
C
A
R F
Y
V H
N
T
L
I
S
Q D
G P
7
  Y C D I
K
E
S
M
G
R H
A
F
W
V
Q
T
P N L
8
  M Q N
H P
R
C
A
Y
D
F
I
S K
L
T
G E V
9
  H V
C I M L F Y
W
Figure 3. Binding motifs of HLA alleles with a low or high RH. The sequence logos displaying the preferences of HLA alleles with a low (A) or high
(B) RH of HIV disease progression. Experimentally verified good-binding peptides for HLA-B5701 and B5801 were used to make the low RH logo (A),
while the good binders of HLA-B3501 and B5301 were used for the high RH logo (B, data from www.immuneepitope.org). These sequence logos
visualize i) to what extent a position in a sequence is conserved (given by the height of a bar, i.e. the information content) and ii) which amino acids
are most frequently found at a particular position (the height of each amino acid in the logo is proportional to the frequency of occurrence at that
position). The information content may vary between log 2 20=4.3, which is obtained if the same amino acid is always observed at a particular
position, and zero, which is obtained if all amino acids occur at the same frequency at a position. Amino acids are colour coded according to their
physicochemical characteristics. Neutral and polar, green; basic, blue; acidic, red; neutral and hydrophobic, black.
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targeted by human individuals with HLA-B57 or B27, who tend to
be long-term non-progressors [1,51]. All these data suggest that
preferential targeting of p24 delays disease progression. However,
previous studies could never rule out the possibility that the
apparent preference for p24 was a side-effect of the high
immunogenicity of p24, causing immune responses to p24 to be
better maintained than other responses in individuals with low
viral load. Our analyses based on HLA-peptide binding predic-
tions conclusively show that HLA alleles associated with slow HIV
disease progression have an intrinsic preference for peptides from
the HIV p24 protein. Our results thereby suggest that the class I
restricted CTL immune response, particularly against p24, plays
a key role in controlling HIV-1 infection.
Why then is preferential targeting of p24 beneficial? The first
reason that comes to mind is that p24 is one of the most
functionally and structurally constrained proteins of HIV. P24
contains a stretch of 20 amino acids which is conserved across
retroviruses, and is essential for viral assembly, maturation, and
infectivity [52]. This region contains a B14 epitope (a low RH
allele), and Wagner et al. [53] found that all mutations abrogating
the CTL response to this epitope drastically reduced the
replication capacity of the virus. In line with this, we found
several HIV epitopes that are presented by protective HLA
Table 1. Predicted p24 epitopes with a high ranking
a HLA-binding affinity score.
..................................................................................................................................................
Epitope
b Position
c HLA
d Rank
e Supertype Confirmation
j
SMM
f ANN
g [38]
h [59]
i
FRDYVDRFY 161 A0101 .10 9 A1s A1s
HQAAMQMLK 60 A0301 3 .10 A3s A3s
RDYVDRFYK 162 A1101 .10 4 A3s A3s
GWMTNNPPIP 116 A2402 8 – A24s A24s
STLQEQIGW 109 A2403 8 .10 A24s A24s
EVIPMFSAL 35 A2601 8 5 A1s A26s ++
RDYVDRFYK 162 A3001 7 .10 A24s A1s .
RDYVDRFYK 162 A3101 .10 2 A3s A3s .
EVIPMFSAL 35 A6802 2 – A2s A2s
MTNNPPIPV 118 A6802 6 – A2s A2s .
EVIPMFSAL 35 A6901 .10 1 A2s A2s
EMMTACQGV 118 A6901 1 8 A2s A2s .
MTNNPPIPV 213 A6901 2 .10 A2s A2s .
DCKTILKAL 197 B0801 9 2 – – ++
EIYKRWIIL 128 B0801 .10 8 – – ++
KRWIILGLNK 130 B2705 3 3 B27s B27s ++
GEIYKRWII 127 B4001 – 6 B44s B44s
REPRGSDIA 97 B4002 8 – B44s B44s
SEGATPQDL 44 B4403 8 – B44s B44s ++
REPRGSDIA 97 B4501 2 – B44s B44s
AEWDRLHPV 78 B4501 3 – B44s B44s .
HPVHAGPIA 84 B5401 3 – B7s B7s .
ISPRTLNAW 15 B5701 2 – B58s B58s ++
STLQEQIGW 109 B5701 4 – B58s B58s ++
QASQEVKNW 176 B5701 6 – B58s B58s ++
STLQEQIGW 109 B5801 2 .10 B58s B58s ++
QASQEVKNW 176 B5801 4 .10 B58s B58s ++
ISPRTLNAW 15 B5801 .10 6 B58s B58s ++
TINEEAAEW 72 B5801 7 5 B58s B58s +
aRanks,10 are considered to be high.
bAll peptides listed are predicted to be transported by TAP [36] and cleaved by the proteasome [35].
cThe position of each epitope is given with respect to HXB2-p24 (as in the HIV-1 immunology database).
dThe HLA molecule by which the epitope is predicted to be presented.
e–indicates that there is no reliable prediction tool for this HLA type.
fThe rank of the peptide among all 9-mers from HIV-1 that are predicted to bind the specific HLA molecule (where 1 denotes the best binding epitope) using the SMM
method.
gThe same predicted rank using a neural network based predictor (NetMHC).
hThe HLA supertype to which the HLA molecule belongs according to Sette et al. [38].
iThe HLA supertype to which the HLA molecule belongs according to Lund et al. [59]).
jPeptides that have been experimentally confirmed to bind the two-digit HLA type are denoted by +, the four-digit HLA allele by ++, and by HLA molecules from the
same supertype as the predicted HLA type by dots.
doi:10.1371/journal.pone.0000920.t001
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e920molecules to be located at the dimer interface of p24, which is
expected to be sensitive to mutations. The peptide binding motifs
of HLA alleles with low and high relative hazards (Figure 3) also
suggest that low RH alleles tend to present peptides that are more
sensitive to mutations, because they prefer tryptophan (W) at
position 9. Tryptophan is the only amino acid coded by a single
triplet. Any mutation in a tryptophan triplet will thus lead to an
amino acid substitution or a stop-codon. Due to the unusual side
chain properties of tryptophan, such amino acid substitutions tend
to affect the protein structure and function. As a consequence,
tryptophan is the most conserved amino acid. HLA alleles with
a high RH, on the other hand, prefer proline (P) at position 2,
which is coded by 4 triplets, and is known to be less conserved than
tryptophan. HLA alleles with a low RH thus seem to preferentially
bind the parts of the HIV genome that are most sensitive to
mutations. This may in part explain why they confer better
protection against disease progression.
Since HIV-1 proteins other than p24 may also contain
functionally and structurally constrained regions, we investigated
if there is a general correlation between the relative hazard of
HLA alleles and the tendency to target constrained parts of the
HIV-1 proteome. We predicted the HIV-1 epitopes for a large
number of HLA alleles and used the entropy of each predicted
epitope as a measure of functional and structural constraint. The
Shannon entropy [32] of each residue in the HIV-1 proteome was
calculated using the HIV-1 protein alignments for clade B
available in the Los Alamos HIV database (September 2005).
Surprisingly, the average entropies of the three predicted best-
binding epitopes for HLA alleles with a low RH were not
significantly different from the ones presented by HLA alleles with
a high RH (Mann-Whitney, p=0.87, unpublished results). There
was also no significant correlation between the entropy score of the
best-binding predicted epitopes and the RH of the HLA
presenting the epitope (p=0.79, unpublished results). Presentation
of conserved HIV epitopes is thus not explaining the difference
between HLA alleles associated with slow and rapid disease
progression.
There are two non-mutually exclusive explanations for this
surprising finding. The first is that targeting conserved epitopes is
required but not sufficient to delay disease progression (see also
[23]). Apart from its conservedness, p24 may have other properties
that explain why CTL responses against p24 are most beneficial.
Possible factors include the fact that p24 is one of the most
immunogenic and abundant HIV proteins. An immature HIV
particle contains approximately 1500 copies of p24, while other
HIV proteins are present at much lower copy numbers [54]. P24
epitopes are therefore expected to induce stronger immune
responses than other HIV epitopes. Additionally, it was recently
shown that p24 can be detected within two hours after the
infection of a target cell, which is well before other HIV-1 proteins
are produced, and before Nef can down-regulate HLA expression
[55]. The origin of the early expressed p24 is probably the large
amount of p24 packaged in viral particles [54]. Preferential
targeting of conserved epitopes from an early and abundantly
expressed, highly immunogenic protein, may hence be the clue to
slowing down disease progression.
A second explanation is that entropy is not the correct measure of
functional and structural constraints. Indeed, peptides that are
hardlyconstrained maynevertheless have a low entropy ifthere isno
strong CTL pressure on the peptide, or if the HLA molecule by
which the peptide is restricted is very rare in the human population.
Conversely, peptides may have a high entropy despite functional or
structural constraint if the CTL pressure on the peptide is so high
that the peptide mutates despite a high viral fitness cost [56]. The
latter is exactly what has been described for p24 epitopes targeted by
elite suppressors of HIV-1 [7]. Despite the lack of correlation
between the relative hazard of HIV disease progression and the
tendency to present peptides with low entropy, preferential targeting
of functionally and structurally constrained regions of HIV-1 may
thus be key to slowing down disease progression.
Figure 4. Crystal structure of a p24 dimer. Entry 1AFV from the protein data bank is shown (PDB, www.rcsb.org/pdb) [44,45]. (A) One monomer is
shown in combined cartoon and surface representation to show the extent of the surface exposed part of the epitopes. For clarity, the other
monomer is shown only in cartoon representation. The epitopes located in the dimer interface are highlighted in red (IW9), yellow (TW10) and green
(DV9), and are also shown in stick representation. (B) A close-up of the dimer interface. The two monomers are shown in dark blue and cyan, and the
TW10 epitopes are shown in green and magenta stick representations. The hydrophobic contact between T110 from one monomer to T110 in the
other monomer is indicated by a dashed line.
doi:10.1371/journal.pone.0000920.g004
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PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e920HLA-B27 was the first HLA that was described to be associated
with slow HIV-1 disease progression [57]. Our analyses reveal an
important difference between HLA-B27 on the one hand and
HLA-B57 and B58 on the other. While the latter two HLA alleles
target at least 3 different p24 peptides with high affinity, HLA-B27
has only one good-binding p24 peptide (see Figure 1). It has been
reported that CTL escape of this epitope caused a rapid increase
of viremia in an HLA-B27-positive long-term non-progressing
child [58]. Our analyses suggest that this abrupt breakage of
protection may be caused by the absence of other protective anti-
p24 CTL responses.
The differences between HLA alleles associated with slow and
rapid disease progression have also been sought in their
frequencies in the human population. Trachtenberg et al. [15]
demonstrated a significant correlation between the population
frequency of HLA supertypes [38,59] and the HIV-1 viral load at
set point in a large group of HIV-1 infected homosexual men.
Scherer et al. [16] extended these results by showing that common
HLA alleles are associated with a lack of CTL responses to known
HIV-1 epitopes, further supporting the idea that HIV-1 is
adapting to the most common HLA molecules in the human
population. Frahm et al. [17] demonstrated that an HLA molecule
associated with a low viral load in a population in which the HLA
is rare, lacked this association in another population where the
HLA is common. Data are conflicting, however, because no
significant correlation could be found between the relative hazard
of HIV disease progression and the population frequency of HLA
molecules [13].
Whatever the effect of the population frequency of HLA
molecules on the rate of HIV disease progression is, the current
study shows that qualitative differences in the epitopes targeted by
different HLA molecules contribute to the association between
HLA molecules and the rate of HIV-1 disease progression.
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